Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In preclinical and clinical trials of 186RNL for treating GBM, ReSPECT-GBM, we delivered up to 20x the absorbed dose of radiation versus standard external beam radiation therapy (EBRT), successfully reducing tumors without significant toxicity.
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial
Details : Rhenium NanoLiposome (RNL™) is designed to safely, effectively and conveniently deliver a very high dose of radiation potentially up to 15 times greater than traditional external beam radiation therapy.
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Investigational drug RNL™ delivers up to fifteen times the absorbed dose of radiation compared to standard external beam radiation therapy.
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
Details : Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $0.4 million
November 05, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Plus Therapeutics
Deal Size : $137.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial
Details : Plus Therapeutics has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of rec...
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Plus Therapeutics Receives Fast Track Designation from FDA for Its Novel Glioblastoma Treatment
Details : RNL is designed to safely, effectively, and conveniently deliver a very high dose of radiation, of up to 25 times greater concentration than currently used external beam radiation therapy, directly into the brain tumor for maximum effect.
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
Details : University of Texas MD Anderson Cancer Center is now an active clinical trial site in Plus Therapeutics' ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI).
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Plus Therapeutics' abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.
Product Name : RNL
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : Rhenium-186
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable